Summary
This article reviews standard treatment modalities for patients with glaucoma and describes 3 classes of drugs which are undergoing development: apraclonidine (aplonidine, ALO 2145), an α2-adrenergic agonist which has been released for clinical use; topical carbonic anhydrase inhibitors, a modification of the systemic carbonic anhydrase inhibitors currently in use; and prostaglandins (PGs), a new class of drugs with topical ocular hypotensive activity.
Standard treatment modalities include parasympathomimetic agents such as pilocarpine, car-bachol, and phospholine iodide, which lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork. A newer form of pilocarpine as a gel produces a longer action. Adrenergic agonist medications, such as epinephrine (adrenaline) and its prodrug dipivefrine (dipivalyl epinephrine), function by increasing uveoscleral outflow and trabecular outflow facility.
A decrease in aqueous formation by the ciliary processes is thought to be the mechanism of action of β-adrenoceptor antagonists, but the physiological basis for this action has not been clearly demonstrated. A newer β-blocker, betaxolol, has relatively selective β2-blocking activity.
Carbonic anhydrase inhibitors are nonbacteriostatic sulphonamide derivatives which decrease aqueous formation by the ciliary body. Almost 50% of patients taking these medications are unable to tolerate them because of their adverse effects, and there is thus much interest in the development of a topical carbonic anhydrase inhibitor with the potential for fewer adverse effects. MK 507 is the most recent and most potent compound in the series of topically active carbonic anhydrase inhibitors.
Apraclonidine hydrochloride is a derivative of clonidine hydrochloride, an α2-adrenergic agonist. Clonidine has previously been shown to lower IOP significantly, but has the potential to produce marked lowering of both systolic and diastolic blood pressures. Its major ocular effect appears to be a decrease in aqueous production. The structural modification to apraclonidine decreases corneal absorption and the drug’s ability to cross the blood-brain barrier, minimising the risk of centrally mediated cardiovascular side effects.
Apraclonidine may also influence secondary avenues of aqueous outflow, such as uveoscleral outflow, and may also affect conjunctival and episcleral vascular flow. It produces a mean decrease in IOP of 25% for as long as 12 hours. Adverse effects include blanching of the conjunctiva, minimal mydriasis and eyelid retraction. This drug has been approved in the US for use in prevention of elevated IOP after argon laser trabeculoplasty and iridotomy, and has potential uses in preventing an IOP rise after YAG laser posterior capsulotomy and cataract surgery in patients already on other antiglaucomatous medications.
Lower doses of certain prostaglandins, especially PGF2α, have produced a dramatic IOP lowering effect. A 10 to 25% decrease in IOP can occur in humans at doses which are probably submaximal, with little or no evidence of intraocular inflammation. There is no effect on pupillary diameter or visual acuity; however, conjunctival hyperaemia, ocular irritation and a foreign body sensation have been noted. It is hoped that new drug analogues will eliminate these adverse effects. The primary mechanism of the ocular hypotensive action of prostaglandins is thought to be an increase in uveoscleral outflow.
Twice-daily doses of the isopropylester derivative of PGF2α (PGF2α-IE) for several days have the ability to consistently reduce IOP by 50 to 60%, to pressures of less than 10mm Hg in cynomolgus monkeys. Prostaglandins are thus the most powerful topical ocular hypotensive agents yet tested in subhuman primates. It remains to be seen whether maximal doses in humans will produce as dramatic an effect. If so, prostaglandin treatment could provide an alternative to surgery for very difficult patients in whom high-risk procedures are necessary in an attempt to achieve these very low IOPs.
Similar content being viewed by others
References
Abraham SV. Miotics in glaucoma. Glaucoma 7(5): 246–248, 1985
Abrams DA, Robin AL, Crandell AS, Caldwell DR, Schnitzer DB, et al. A limited comparison of apraclonidine dose response in subjects with normal or increased intraocular pressure. American Journal of Ophthalmology 108: 230–237, 1989
Abrams DA, Robin AL, Pollack IP, et al. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Archives of Ophthalmology 105: 1205–1207, 1987
American Academy of Ophthalmology, Quality of Care Committee, Glaucoma Panel. Primary open-angle glaucoma preferred practice pattern. Epidemiology and magnitude, p.2, February 25, 1989
Anderson CJ, Kaufman PL, Sturm RJ. Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin. American Journal of Ophthalmology 86: 516–519, 1978
Anderson DR. The management of elevated intraocular pressure with normal optic discs and visual fields: therapeutic approach based on high risk factors. Survey of Ophthalmology 21: 479–489, 1977
Axelsson U, Holmberg A. The frequency of cataract after miotic therapy. Acta Ophthalmologica 44: 421–429, 1966
Barany EH, Rohen JW. Localized contraction and relaxation within the ciliary muscle of the vervet monkey (Cercopithecus ethiops). In Rohen JW (Ed.) The structure of the eye, second symposium, pp. 287–311, Schattauer-Verlag, Stuttgart, 1965
Becker B. The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor, Diamox. American Journal of Ophthalmology 39: 177–183, 1955
Beitch BR, Eakins KE. The effects of prostaglandins on the intraocular pressure of the rabbit. British Journal of Pharmacology 37: 158–167, 1969
Bill A. Formation and drainage of aqueous humor in cats. Experimental Eye Research 5: 185–190, 1966a
Bill A. The routes for bulk drainage of aqueous humor in rabbits with and without cyclodialysis. Documenta Ophthalmologica 20: 157–169, 1966b
Bill A. Effects of atropine and pilocarpine on aqueous humor dynamics in cynomolgus monkeys (Macaca irus). Experimental Eye Research 6: 120–125, 1967
Bill A. Aqueous humor dynamics in monkeys (Macaca irus and Cercopithecus ethiops). Experimental Eye Research 11: 195–206, 1971
Bill A. Blood circulation and fluid dynamics in the eye. Pharmacological Reviews 55: 383–417, 1975
Bill A, Heilmann K. Ocular effects of clonidine in cats and monkeys (Macaca irus). Experimental Eye Research 21: 481–488, 1978
Bill A, Phillips I. Uveoscleral drainage of aqueous humor in human eyes. Experimental Eye Research 12: 275–281, 1971
Blanchard DL. Adrenergic-associated symblepharon. Glaucoma 9: 18–20, 1987
Bleiman BS, Schwartz AL. Paradoxical intraocular pressure response to pilocarpine. Archives of Ophthalmology 97: 1305–1306, 1979
Block ER, Rostand RA. Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger? Survey of Ophthalmology 23: 169–172, 1978
Boger WP. Short-term ‘escape’ and long-term ‘drift’: the dissipation effects of the beta adrenergic blocking agents. Survey of Ophthalmology 28: 235–240, 1983
Bovino JA, Marcus DF. The mechanism of transient myopia induced by sulfonamide therapy. American Journal of Ophthalmology 78: 327, 1974
Bron AM, Lippa EA, Hofmann HM, Reicht BI, Royer JG, et al. MK 927: a topically effective carbonic anhydrase inhibitor in patients. Archives of Ophthalmology 107: 1143–1146, 1989
Brown RH, Stewart RH, Lynch MG, et al. ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery. Ophthalmology 95: 378–384, 1988
Brown SVL, Thomas JV, Belcher III CD. Effect of pilocarpine in treatment of intraocular pressure elevation following Neodymium: YAG laser posterior capsulotomy. Ophthalmology 92: 354–359, 1985
Camras CB, Bito LZ. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2α. Current Eye Research 1: 205–209, 1981
Camras CB, Feldman SG, Podos SM, et al. Inhibition of the epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. American Journal of Ophthalmology 100: 169–175, 1985
Camras CB, Siebold EC, Lustgarten JS, Seale JB, Frisch SC, et al. Maintained reduction of intraocular pressure by prostaglandin F2α-1-isopropylester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 96: 1329–1337, 1989
Chandler PA, Grant WM. Diaǵnosis and treatment of glaucomas in adults. In Epstein DL (Ed.) Glaucoma, 3rd ed., 5, pp. 129–180, Lea & Febiger, Philadelphia, 1986
Channell MM, Beckman H. Intraocular pressure changes after Neodymium:YAG laser posterior capsulotomy. Archives of Ophthalmology 102: 1024–1026, 1984
Cole DF. Secretion of the aqueous humor. Experimental Eye Research 25 (Suppl.): 161–176, 1977
Coleman AL, Robin AL, Pollack IP. Apraclonidine hydrochloride. Ophthalmology Clinics of North America 2: 97–108, 1989a
Coleman AL, Robin AL, Rudikoff MT, Pollack IP. A comparison of the cardiovascular effects and intraocular pressure lowering of apraclonidine and timolol. Investigative Ophthalmology and Visual Science 29 (Suppl.): 22, 1989b
Crawford K, Kaufman PL. Pilocarpine antagonizes PGF2α-induced ocular hypotension: evidence for enhancement of uveoscleral outflow by PGF2α. Archives of Ophthalmology 105: 1112–1116, 1987
Crawford K, Kaufman PL, Gabelt BT. Effects of topical PGF2α on aqueous humor dynamics in cynomolgus monkeys. Current Eye Research 6: 1035–1044, 1987
Crawford K, Kaufman PL, Majors LJ. Dose-response relationships between PGF2α-IE and IOP, refraction and pupil diameter in cynomolgus monkeys. Investigative Ophthalmology and Visual Science 30 (Suppl.): 24, 1989
Cyrlin JS, Beckman H. Low-dose oral glycerin for the prevention of post-laser IOP elevation. Investigative Ophthalmology and Visual Science 28 (Suppl.): 272, 1987
DeRoetth Jr A. Lens opacities in patients on phospholine iodide therapy. American Journal of Ophthalmology 62: 619–628, 1966
Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Archives of Ophthalmology 95: 1378–1382, 1977
Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Annals of Internal Medicine 112: 120–125, 1990
Flohr MJ, Robin AL, Kelley JS. Early complications following Q-switched Neodymiunr:YAG laser posterior capsulotomy. Ophthalmology 92: 360–363, 1985
Foss RH. Local application of Diamox: an experimental study of its effects on the intraocular pressure. American Journal of Ophthalmology 39: 336–339, 1955
Friedman Z, Allen RC, Ralph SM. Topical acetazolamide and methazolamide delivered by contact lens. Archives of Ophthalmology 103: 963, 1985
Gabelt BT, Kaufman PL. Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey. Experimental Eye Research 49: 389–402, 1989
Gardner KM, Straatsma BR, Petit TH. Neodymium:YAG laser posterior capsulotomy: the first 100 cases at UCLA. Ophthalmic Surgery 16: 24–28, 1985
George JL, Sirbat D, Lesure P, Lippa E, Royer J, et al. MK-417 vs MK-927: multiple-dose efficacy comparison of two topical carbonic anhydrase inhibitors. Investigative Ophthalmology and Visual Science 30 (Suppl.): 98, 1989
Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 95: 1217–1220, 1988
Gilmartin B, Hogan RE, Thompson SM. The effect of timolol maleate on tonic accommodation, tonic vergence, and pupil diameter. Investigative Ophthalmology and Visual Science 25: 763–770, 1984
Giufrè G. The effects of prostaglandin F2α in the human eye. Graefe’s Archive for Clinical and Experimental Ophthalmology 222: 139–141, 1985
Grant WM. Antiglaucoma drugs: problems with carbonic anhydrase inhibitors. In Leopold IM (Ed.) Symposium on ocular therapy 6, pp. 19–38, Mosby, St. Louis, 1972
Green H, Leopold IH. Effects of locally administered Diamox. American Journal of Ophthalmology 40: 137–139, 1955
Groeneboer MC, Hoyng PFG, Kuizenga A. Prostaglandin F2α iso-propylester versus iloprostphenacylester in rabbit and beagle eyes. Current Eye Research 8: 131–138, 1989
Haimann MH, Phelps CD. Prophylactic timolol for the prevention of high intraocular pressure after cataract extraction. Ophthalmology 88: 233–238, 1981
Harrison R, Kaufmann CS. Clonidine: effects of a topically administered solution on intraocular pressure and blood pressure in open-angle glaucoma. Archives of Ophthalmology 95: 1368–1373, 1977
Hayashi MT, Yablonski ME, Bito LZ, Miranda OC. The effects of ocular hypotensive doses of prostaglandins (PGs) and their esters on aqueous humor dynamics of cat eyes. Proceedings of the International Society for Eye Research 4: 14, 1986
Heilman K, Richardson KT (Eds). Glaucoma and glaucoma suspects. In Glaucoma: conceptions of a disease, pp. 2-6, W.B. Saunders Company, Philadelphia, London, Toronto, Georg Thieme Publishers, Stuttgart, 1978
Henry JC, Krupin T, Schultz J, et al. Increased intraocular pressure following Neodymium-YAG laser iridectomy. Archives of Ophthalmology 104: 178, 1986
Higginbotham EJ. Topical carbonic anhydrase inhibitors. In Zimmerman TJ & Kooner KS (Eds) Ophthalmology clinics of North America pp. 113–130, Saunders, Philadelphia, March 1989
Higginbotham E, Kao SF, Kass M, Weinreb R, Lippa E, et al. Once-daily and twice-daily treatment with the topical carbonic anhydrase inhibitor MK-927. Investigative Ophthalmology and Visual Science 30 (Suppl.): 23, 1989
Hodapp E, Kolker AE, Kass MA, et al. The effect of topical clonidine on intraocular pressure. Archives of Ophthalmology 99: 1208–1211, 1981
Hollands RH, Drance SM, Schulzer M. The effect of intracameral carbachol on intraocular pressure after cataract extraction. American Journal of Ophthalmology 104: 225–228, 1987a
Hollands RH, Drance SM, Schulzer M. The effect of acetylcholine on early postoperative intraocular pressure. American Journal of Ophthalmology 103: 749–783, 1987b
Hoskins HD Jr, Kass M. Becker-Shaffer’s diagnosis and therapy of the glaucomas, 6th ed., pp. 2–9, C.V. Mosby, St Louis, MO, 1989
Hotchkiss ML, Robin AL, Pollack IP, et al. Non-steroidal anti-inflammatory agents after argon laser trabeculoplasty. Ophthalmology 91: 969–976, 1984
Innemee HC, Hermans AJM, van Zweiten PA. The influence of clonidine on intraocular pressure after topical application to the eyes of anesthetized cats. Graefe’s Archive for Clinical and Experimental Ophthalmology 212: 19–27, 1979
Innemee HC, van Zweiten PA. The central ocular hypotensive effect of clonidine. Graefe’s Archive for Clinical and Experimental Ophthalmology 210: 93–102, 1979
Isenberg SJ, Green BF. Effect of phenylephrine hydrochloride on conjunctival PO2. Archives of Ophthalmology 102: 1185–1186, 1984
Jampel HD. Hypotony following instillation of apraclonidine for increased intraocular pressure after trabeculoplasty. American Journal of Ophthalmology 108: 191–192, 1989
Jampel HD, Robin AL, Quigley HA, Pollack IP. Apraclonidine hydrochloride: a one-week dose-response study. Archives of Ophthalmology 106: 1069–1073, 1988
Johnson DH, Epstein DL, Allen RC, Boys-Smith J, Campbell D, et al. A one year multicenter clinical trial of pilocarpine gel. American Journal of Ophthalmology 97: 723–729, 1984
Johnson DH, Kenyon KR, Epstein DL, Van Buskirk EM. Corneal changes during pilocarpine gel therapy. American Journal of Ophthalmology 101: 13–15, 1986
Kalina PH, Shetler DJ, Lewis RA, Kullerstrand LJ, Brubaker RF. 6-amino-2-benzothiazole-sulfonamide, the effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmology 95: 772–777, 1988
Kass MA. Topical carbonic anhydrase inhibitors. American Journal of Ophthalmology 107: 280–282, 1989
Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology 88: 261–265, 1981
Kass M, Korey M, Gordon M, Becker B. Timolol and acetazolamide: a study of concurrent administration. Archives of Ophthalmology 100: 921–942, 1982
Kass MA, Podos SM, Moses RA, Becker B. Prostaglandin E1 and aqueous humor dynamics. Investigative Ophthalmology 11: 1022–1027, 1972
Kaufman PL. Aqueous humor outflow. In Zadunaisky& Davson (Eds) Current topics in eye research, Vol. 4, pp. 97–138, Academic Press, New York, 1984
Kaufman PL. Aqueous humor dynamics. In Duane TD (Ed.) Clinical ophthalmology, Vol. 3, pp. 1–24, Harper & Row, Philadelphia, 1985
Kaufman PL. Recent advances in the physiology and pharmacology of the ciliary muscle in relation to aqueous humor outflow. Proceedings of the International Society for Eye Research 5: 73, 1988
Kaufman PL, Bárány EH. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgous monkey. Investigative Ophthalmology 15: 793–807, 1976
Kaufman PL, Erickson KA, Neider MW. Echothiophate iodide cataracts in monkeys. Archives of Ophthalmology 101: 125–128, 1983
Kelly RGM, Starr MS. Effects of prostaglandins and a prostaglandin antagonist on intraocular pressure and protein in the monkey eye. Canadian Journal of Ophthalmology 6: 205–211, 1971
Kerstetter JR, Brubaker RF, Wilson SE, Kullerstrand LJ. Prostaglandin F2α-1-isopropylester lowers intraocular pressure without decreasing aqueous flow. American Journal of Ophthalmology 105: 30–34, 1988
Kinsey VE. Ion movement in ciliary processes. In Bittar EE (Ed.) Membranes and ion transport, Vol. 3, pp. 185–209, Wiley & Sons, New York, 1971
Kitazawa Y, Sugiyama K, Taniguchi T. The prevention of an acute rise in intraocular pressure following Q-switched Nd:YAG laser iridotomy with clonidine. Graefe’s Archive for Clinical and Experimental Ophthalmology 227: 13–16, 1989a
Kitazawa Y, Taniguchi T, Sugiyama K. Use of apraclonidine to reduce acute intraocular pressure rise following Q-switched Nd:YAG laser iridotomy. Ophthalmic Surgery 20: 49–52, 1989b
Knupp JA, Shields MB, Mandell AI, Hurvitz LM, Spaeth GL. Combined timolol & epinephrine therapy for open angle glaucoma. Survey of Ophthalmology 28: 280–284, 1983
Krieglstein GK, Langham ME, Leydecker W. The peripheral and central neural actions of clonidine in normal and glaucomatous eyes. Investigative Ophthalmology and Visual Science 17: 149–158, 1978
Lee DA, Topper JE, Brubaker RF. Effect of clonidine on aqueous humor flow in normal human eyes. Experimental Eye Research 38: 239–246, 1984a
Lee P-Y, Podos SM, Severin C. Effect of prostaglandin F2α on aqueous humor dynamics of rabbit, cat and monkey. Investigative Ophthalmology and Visual Science 25: 1087–1093, 1984b
Lee P-Y, Shoo H, Xu L, Qu C-K. The effect of prostaglandin F2α on intraocular pressure in normotensive human subjects. Investigative Ophthalmology and Visual Science 29: 1474–1477, 1988
Lewis RA. Medical therapy of glaucoma. In Duane TD & Jaeger EA (Eds) Clinical ophthalmology, Vol. 3, pp. 1–24, Lippincott, Philadelphia, 1988
Lewis RA, Schoenwald RD, Barfknecht CF, Phelps CD. Aminozolamide gel, a trial of a topical carbonic anhydrase inhibitor in ocular hypertension. Archives of Ophthalmology 104: 842–844, 1986
Lewis RA, Schoenwald RD, Eller MG, Barfknecht CF, Phelps CD. Ethoxzolamide analogue gel, a topical CAI. Archives of Ophthalmology 102: 1821–1824, 1984
Lichter PR, Newman LP, Wheeler NC, Beall OV. Patient tolerance to carbonic anhydrase inhibitors. American Journal of Ophthalmology 85: 495–502, 1978
Liu JHK, Neufeld AH. Study of central regulation of intraocular pressure using ventriculocisternal perfusion. Investigative Ophthalmology and Visual Science 26: 136–143, 1985
Lütjen-Drecoll E, Lonnerholm G, Eichora M. Carbonic anhydrase distribution in the human and monkey eye by light and electron microscopy. Graefe’s Archive for Clinical and Experimental Ophthalmology 220: 285–291, 1983
Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2α. Experimental Eye Research 47: 761–769, 1988
Macoul KL, Pavan-Langston D. Pilocarpine ocusert system for sustained control of ocular hypertension. Archives of Ophthalmology 93: 587–590, 1975
Mandell AI, Bruce LA, Khalifa MA. Reduced myopia with pilocarpine gel. Annals of Ophthalmology 20: 133–135, 1988
Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new prodrug in the treatment of glaucoma. Ophthalmology 85: 268, 1978
Maren TH. Teratology and carbonic anhydrase inhibition. Archives of Ophthalmology 78: 327, 1974
Maren TH. Relations between structure and biological activity of sulfonamides. Annual Review of Pharmacology and Toxicology 16: 309–327, 1976
Maren TH. The development of ideas concerning the role of carbonic anhydrase in the secretion of aqueous humor relation to the treatment of glaucoma. In Drance SM & Neufeld AH (Eds) Glaucoma: applied pharmacology in medical treatment, pp. 325–355, Grune and Stratton, Orlando, Florida, 1984
Maren TH, Jankowska L. Ocular pharmacology of sulfonamides: the cornea as barrier and depot. Current Eye Research 4: 399–408, 1985
Maren TH, Jankowska L, Sanyal G, Edelhauser HF. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Experimental Eye Research 36: 457–479, 1983
Migliori ME, Beckman H, Channell MM. Intraocular pressure changes after Neodymium:YAG laser capsulotomy in eyes pretreated with timolol. Archives of Ophthalmology 105: 473–475, 1987
Mogk LG, Cyrlin MN. Blood dyscrasias and carbonic anhydrase inhibitors. Ophthalmology 95: 768–771, 1988
Morrison JC, Robin AL. Adjunctive glaucoma therapy: a comparison of apraclonidine and dipivefrin when added to timolol maleate. Ophthalmology 96: 3–7, 1989
Moses RA. The effect of intraocular pressure on resistance to outflow. Survey of Ophthalmology 22: 88–100, 1977
Neufeld AH, Bartels SP, Liu JHK. Laboratory and clinical studies on the mechanism of action of timolol. Survey of Ophthalmology 28: 286–290, 1983
Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkey. Experimental Eye Research 48: 707–716, 1989
Packer AJ, Fraiolo AJ, Epstein DL. The effect of timolol and acetazolamide on transient intraocular pressure elevation following cataract extraction with alpha-chymotrypsin. Ophthalmology 88: 239–243, 1981
Parfitt AM. Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis. Archives of Internal Medicine 124: 736–740, 1969
Petursson G, Cole R, Hanna C. Treatment of glaucoma using minidrops of clonidine. Archives of Ophthalmology 102: 1180–1181, 1984
Pollack IP, Brown RH, Crandall AS, Robin AL, Stewart RH, et al. Effectiveness of apraclonidine in preventing the rise in intraocular pressure after neodymium:YAG posterior capsulotomy. Transactions of the American Ophthalmological Society 86: 461–472, 1988a
Pollack IP, Brown RH, Crandall AS, Robin AL, Stewart RH, et al. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% ALO 2145. Archives of Ophthalmology 106: 754–757, 1988b
Quigley HA, Addicks EM, Green WR, et al. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Archives of Ophthalmology 99: 635–640, 1981
Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Archives of Ophthalmology 100: 135–146, 1982
Quigley HA, Pollack IP, Harbin TS. Pilocarpine ocusert. Archives of Ophthalmology 93: 771–775, 1975
Ralli R. Clonidine effect on the intraocular pressure and eye circulation. Acta Ophthalmologica 125: 37, 1975
Rehany U, Rose L, Mazor Z, Ticho U. Visual effects of echothiophate (phospholine) iodide and pilocarpine hydrochloride in young adults. Glaucoma 2: 456–460, 1980
Richter CU, Arzeno G, Pappas HR, et al. Prevention of intraocular pressure elevation following Nd:YAG laser posterior capsulotomy. Archives of Ophthalmology 103: 912–915, 1985
Ritch R, Lowe RF, Reyes A. Therapeutic overview of angle-closure glaucoma. In Ritch et al. (Eds) The Glaucomas, Vol. 2, Section 48, pp. 855–864, C.V. Mosby Co., Baltimore, 1989
Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. Archives of Ophthalmology 106: 912–915, 1988
Robin AL. The role of apraclonidine hydrochloride in laser therapy for glaucoma. Transactions of the American Ophthalmological Society 97: 729–761, 1989
Robin AL, Novack GD. Alpha 2 agonist in the therapy of glaucoma. In Drance et al. (Eds) Glaucoma: applied pharmacology in medical treatment, Williams & Wilkins, Baltimore, in press, 1991
Robin AL, Pollack IP, deFaller JM. Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. Archives of Ophthalmology 105: 1208–1211, 1987a
Robin AL, Pollack IP, House B, et al. Effects of ALO 2145 on intraocular pressure following argon laser trabeculoplasty. Archives of Ophthalmology 105: 646–650, 1987b
Rubenstein MA, Bucy JG. Acetazolamide induced renal calculi. Journal of Urology 114: 610–612, 1975
Ruiz RS, Wilson CA, Musgrove RH, et al. Management of increased intraocular pressure after cataract extraction. American Journal of Ophthalmology 103: 487–491, 1987
Schottensteinai EM. Intraocular pressure. In Ritch et al. (Eds) The Glaucomas, Vol. 1, Section 15, pp. 301–317, C.V. Mosby Co., Baltimore, 1989
Schrems W, Eichelbronner O, Krieglstein GK. The immediate IOP response of ND-YAG-laser iridotomy and its prophylactic treatability. Acta Ophthalmologica 62: 673–680, 1984
Schwartz JS, Weinstock SM. Side effects of topical epinephrine therapy. Glaucoma 5: 21–23, 1983
Serdahl C, Galustian J, Lewis RA. Effects of apraclonidine on conjunctival oxygen tension. Investigative Ophthalmology and Visual Science 30 (Suppl.): 22, 1989
Shore JH, Fraunfelder FT, Meyer SM. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. Journal of Clinical Psychopharmacology 7: 264–267, 1987
Shrader CE, Thomas JV, Simmons RJ. Relationship of patient age and tolerance to carbonic anhydrase inhibitors. American Journal of Ophthalmology 96: 730–733, 1983
Silverstone DE, Novack GD, Kelley EP, et al. Prophylactic treatment of intraocular pressure elevations after neodymium:YAG laser posterior capsulotomies and extracapsular cataract extractions with levobunolol. Ophthalmology 95: 713–718, 1988
Stewart RH, Kimbrough RL, Smith JP, Ward RL. Long acting pilocarpine gel: a dose-response in ocular hypertensive subjects. Glaucoma 6: 182–185, 1984
Stitzel RE, Irish III JM. Water, electrolyte metabolism and diuretic agents. In Craig CR & Stitzel RE (Eds) Modern pharmacology, pp. 328–329, Little Brown, Boston, 1982
Swedish Adverse Drug Reactions Advisory Committee. Acetazolamide: pancytopenia. Bulletin SADRAC No. 46, 1985
Tamm E, Lütjen-Drecoll E, Rittig M, Rohen JW. Connective tissue changes in the uveoscleral pathways of primate eyes after treatment with prostaglandin F2α. Investigative Ophthalmology and Visual Science 30 (Suppl.): 99, 1989
Terry AC, Stark WJ, Maumenee AE, et al. Neodymium:YAG laser for posterior capsulotomy. American Journal of Ophthalmology 86: 716–720, 1983
Thomas JV, Simmons RJ, Belcher CD. Argon laser trabeculoplasty in the presurgical glaucoma patient. Ophthalmology 89: 187–197, 1982
Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Investigative Ophthalmology and Visual Science 28: 477–481, 1987
VanBuskirk EM, Weinreb RN, Berry DP, Lustgarten JS, Podos SM, et al. Betaxolol in patients with glaucoma and asthma. American Journal of Ophthalmology 101: 531–534, 1986
Villumsen J, Alm A. Prostaglandin F2α-isopropylester eye drops: effects in normal human eyes. British Journal of Ophthalmology 73(6): 419–426, 1989
Villumsen J, Alm A, Soderstrom M. Prostaglandin F2α-isopropylester eye drops: effect on intraocular pressure in open angle glaucoma. British Journal of Ophthalmology 73(12): 975–979, 1989
Waitzman MB, King CD. Prostaglandin influences on intraocular pressure and pupil size. American Journal of Physiology 212: 329–334, 1967
Weinreb RN, Kass MA, Lippa EA, et al. MS-507 vs MK-417: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 97 (Suppl. 1): 124, 1990
Weinreb RN, Ruderman J, Juster R, et al. Immediate intraocular pressure response to argon laser trabeculoplasty. American Journal of Ophthalmology 95: 279–286, 1983
West DR, Lischwe TD, Thompson VM, et al. Comparative efficacy of the beta-blockers for the prevention of increased intraocular pressure after cataract extraction. American Journal of Ophthalmology 106: 168–173, 1988
Zimmerman TJ. Acetazolamide and methazolamide. Annals of Ophthalmology 10: 509–510, 1978
Zimmerman TJ. Pilocarpine. Ophthalmology 88: 85–88, 1981
Zimmerman TJ. Mechanism of action of topical epinephrine. Editorial. Annals of Ophthalmology 16: 307–308, 1984
Zimmerman TJ, Baumann JD, Hetherington J. Side effects of timolol. Survey of Ophthalmology 2: 243–249, 1983
Zimran A, Beutler E. Can the risk of acetazolamide-induced aplastic anemia be decreased by periodic monitoring of blood cell counts? Editorial. American Journal of Ophthalmology 104: 654–658, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hurvitz, L.M., Kaufman, P.L., Robin, A.L. et al. New Developments in the Drug Treatment of Glaucoma. Drugs 41, 514–532 (1991). https://doi.org/10.2165/00003495-199141040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199141040-00002